Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Rare Disease
Alexion gets rare-disease-focused Wilson
by Lisa M. Jarvis
April 15, 2018
| A version of this story appeared in
Volume 96, Issue 16
Alexion Pharmaceuticals will pay roughly $855 million to acquire Wilson Therapeutics, a Swedish biotech firm focused on treatments for rare diseases. The move comes as Alexion tries to refill its pipeline and right its business in anticipation of a drop in sales of its rare-disease treatment Soliris. The centerpiece of the all-cash purchase is WTX101, a copper-binding agent in Phase III studies to treat Wilson disease, a rare genetic disorder marked by accumulation of copper in the liver, brain, and eyes.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X